SCHEMBL13660727

SCHEMBL13660727

Cc1ccn2ncccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 7/20 0.36
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
RPS6KA5 O75582 2/20 0.35
ELANE P08246 1/20 0.34
DYRK1A Q13627 2/20 0.33
CCNK O75909 2/20 0.33
CDK12 Q9NYV4 2/20 0.33
EGFR P00533 1/20 0.33
KDR P35968 1/20 0.33
NPC1 O15118 2/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
NOS2 P35228 1/20 0.32
HSP90AA1 P07900 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
RAB9A P51151 1/20 0.32
RAPGEF4 Q8WZA2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5019489 0.82 MAP4K4 (0.44) MAP4K4HTTDYRK1AEGFRKDR
SCHEMBL8887892 0.77 MAP4K4 (0.40) MAP4K4ALDH1A1SMN1; SMN2ELANEEGFR
SCHEMBL12156330 0.76 NPC1 (0.34) MAP4K4ELANENPC1NOS3NOS2
SCHEMBL18805605 0.73 MAP4K4 (0.36) MAP4K4ALDH1A1HTTSMN1; SMN2HSD17B10
SCHEMBL29416290 0.73 NOTUM (0.36) MAP4K4RPS6KA5ELANEDYRK1AEGFR
SCHEMBL5495779 0.73 MAP4K4 (0.44) MAP4K4ALDH1A1HTTSMN1; SMN2HSD17B10
SCHEMBL19434099 0.72 DRD4 (0.37) MAP4K4ALDH1A1HTTSMN1; SMN2HSD17B10
SCHEMBL12603993 0.72 MAP4K4 (0.33) MAP4K4ALDH1A1HTTSMN1; SMN2HSD17B10
SCHEMBL19756599 0.72 MAP4K4 (0.38) MAP4K4ALDH1A1HTTSMN1; SMN2HSD17B10
SCHEMBL1701673 0.72 MAP4K4 (0.30) MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022174253-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2022-08-18 WO disclosed
WO-2021050964-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2021-03-18 WO disclosed
EP-3744721-A1 CONDENSED CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISM Shionogi & Co., Ltd (JP) 2020-12-02 EP disclosed
WO-2020065614-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 WO disclosed
WO-2019062802-A1 ISOXAZOLINE DERIVATIVES AND THEIR USES IN AGRICULTURE RELATED APPLICATION DONGGUAN HEC TECH R & D CO., LTD. (CN) 2019-04-04 WO disclosed
EP-3208271-A2 NITROGEN-CONTAINING POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT USING SAME LG Chem, Ltd. (KR) 2017-08-23 EP disclosed
US-7608717-B2 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-10-27 US disclosed
US-20080070943-A1 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070943-A1 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2C MAP4K4 1271/4885ALDH1A1 1019/4885HTT 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.